ATE179210T1 - Gentechnologisch hergestellte antikörper - Google Patents

Gentechnologisch hergestellte antikörper

Info

Publication number
ATE179210T1
ATE179210T1 AT93905306T AT93905306T ATE179210T1 AT E179210 T1 ATE179210 T1 AT E179210T1 AT 93905306 T AT93905306 T AT 93905306T AT 93905306 T AT93905306 T AT 93905306T AT E179210 T1 ATE179210 T1 AT E179210T1
Authority
AT
Austria
Prior art keywords
pct
date sep
sec
melanoma
antiidiotypic
Prior art date
Application number
AT93905306T
Other languages
English (en)
Inventor
Norman Hardman
Gerd Pluschke
Brendan Murray
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE179210T1 publication Critical patent/ATE179210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT93905306T 1992-03-17 1993-03-05 Gentechnologisch hergestellte antikörper ATE179210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92810188 1992-03-17

Publications (1)

Publication Number Publication Date
ATE179210T1 true ATE179210T1 (de) 1999-05-15

Family

ID=8211884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93905306T ATE179210T1 (de) 1992-03-17 1993-03-05 Gentechnologisch hergestellte antikörper

Country Status (12)

Country Link
US (1) US5866124A (de)
EP (1) EP0640131B1 (de)
JP (1) JPH07504802A (de)
AT (1) ATE179210T1 (de)
AU (1) AU673347B2 (de)
CA (1) CA2130173A1 (de)
DE (1) DE69324579T2 (de)
DK (1) DK0640131T3 (de)
ES (1) ES2131107T3 (de)
GR (1) GR3030702T3 (de)
MX (1) MX9301500A (de)
WO (1) WO1993019180A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580758A4 (de) * 1991-04-18 1995-04-05 Sinai School Medicine Rekombinante antikörper gegen menschlichen immunschwächevirus.
EP0674907A3 (de) * 1994-03-21 1996-03-13 Ciba Geigy Ag Antikörper-Trägerprotein-Konjugate, zur Verwendung bei der aktiven Immunotherapie.
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
US20060223096A1 (en) * 2005-03-25 2006-10-05 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
WO2010045495A2 (en) * 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
EP2764025B1 (de) * 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antikörper gegen hmw-maa
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
EP3774881A1 (de) 2018-04-02 2021-02-17 Amgen Inc. Erenumab-zusammensetzung und verwendungen davon
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141783B2 (de) * 1983-11-07 1993-06-16 The Wistar Institute Durch antiidiotype Antikörper induzierte immune Antwort zu Tumoren und Viren
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
JPH03501209A (ja) * 1988-05-17 1991-03-22 フェロン、ソルダノ 抗ヒト高分子量メラノーマ関連抗原に対する抗イディオタイプ抗体
CA2065414C (en) * 1989-09-15 2007-05-15 Tse-Wen Chang Treatment of autoimmune disease
ATE132906T1 (de) * 1989-11-14 1996-01-15 New York Medical College Neuartige antiidiotypische monoklonale antikörper

Also Published As

Publication number Publication date
GR3030702T3 (en) 1999-11-30
EP0640131B1 (de) 1999-04-21
DK0640131T3 (da) 1999-11-01
US5866124A (en) 1999-02-02
AU3631393A (en) 1993-10-21
JPH07504802A (ja) 1995-06-01
ES2131107T3 (es) 1999-07-16
DE69324579T2 (de) 1999-09-23
DE69324579D1 (de) 1999-05-27
AU673347B2 (en) 1996-11-07
WO1993019180A1 (en) 1993-09-30
MX9301500A (es) 1993-12-01
EP0640131A1 (de) 1995-03-01
CA2130173A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
DE69324579D1 (de) Gentechnologisch hergestellte antikörper
DE59508864D1 (de) MONOKLONALER ANTIKÖRPER GEGEN CD44v6
ES2190434T3 (es) Anticuerpos recombinantes especificos para tnf-alfa.
HUP9900902A2 (hu) Vegyületek és eljárások a tuberkulózis diagnosztikájához és immunterápiájára
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ATE407952T1 (de) Mutierte nicht aktivierende igg2 domäne und diese sequenz enthaltende anti-cd3 antikörper
ATE240395T1 (de) Antikörper gegen e-selektin
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
ATE207080T1 (de) Multivalente antigen-bindende proteine
ATE237687T1 (de) Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
EP0954529A4 (de) Porphyromonas gingivalis Antigen zur Diagnose und Behandlung von Periodontitis
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
DE69721485D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendungen
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DE69024758D1 (de) Neuartige antiidiotypische monoklonale Antikörper
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
GB9715177D0 (en) Medicament
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee